» Articles » PMID: 39275164

Okinawa-Based Nordic Diet Decreases Plasma Glial Fibrillary Acidic Protein Levels in Type 2 Diabetes Patients

Overview
Journal Nutrients
Date 2024 Sep 14
PMID 39275164
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated levels of glial fibrillary acidic protein (GFAP) in plasma reflect neuroinflammation and are linked to cognitive decline. Preclinical studies show that dietary change can attenuate astrocyte reactivity and neuroinflammation. In the current study, we investigate if the Okinawa-based Nordic (O-BN) diet alters plasma GFAP levels in patients with Type 2 Diabetes (T2D), a metabolic disorder associated with cognitive disturbances and an increased risk of dementia. Plasma GFAP levels were measured in T2D patients (n = 30) at baseline, after 3 months of the diet, and after a subsequent 4 months of unrestricted diets. The GFAP levels decreased significantly after 3 months of the diet ( = 0.048) but reverted to baseline levels after 4 months of unrestricted diets. At baseline, the GFAP levels correlated significantly with levels of the neurodegeneration marker neurofilament light polypeptide (r = 0.400*) and, after correcting for age, sex, and body mass index, with proinflammatory plasma cytokines (ranging from r = 0.440* to r = 0.530**) and the metabolic hormone islet amyloid polypeptide (r = 0.478*). We found no correlation with psychological well-being. These results suggest that the O-BN diet reduces neuroinflammation in T2D patients and may thus be an important preventive measure for managing T2D and reducing the risk of neurodegenerative disorders.

Citing Articles

Dietary Factors and Interventions for Cognitive Impairment and Dementia.

Dawson A, Willette A Nutrients. 2025; 17(2.

PMID: 39861340 PMC: 11767454. DOI: 10.3390/nu17020210.

References
1.
Ley S, Hamdy O, Mohan V, Hu F . Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014; 383(9933):1999-2007. PMC: 4751088. DOI: 10.1016/S0140-6736(14)60613-9. View

2.
Heimfarth L, Passos F, Monteiro B, Araujo A, Junior L, Quintans J . Serum glial fibrillary acidic protein is a body fluid biomarker: A valuable prognostic for neurological disease - A systematic review. Int Immunopharmacol. 2022; 107:108624. DOI: 10.1016/j.intimp.2022.108624. View

3.
Doorn K, Goudriaan A, Blits-Huizinga C, Bol J, Rozemuller A, Hoogland P . Increased amoeboid microglial density in the olfactory bulb of Parkinson's and Alzheimer's patients. Brain Pathol. 2013; 24(2):152-65. PMC: 8029318. DOI: 10.1111/bpa.12088. View

4.
Kim K, Shin K, Chang K . GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Cells. 2023; 12(9). PMC: 10177296. DOI: 10.3390/cells12091309. View

5.
Ohlsson B, Roth B, Larsson E, Hoglund P . Calprotectin in serum and zonulin in serum and feces are elevated after introduction of a diet with lower carbohydrate content and higher fiber, fat and protein contents. Biomed Rep. 2017; 6(4):411-422. PMC: 5374938. DOI: 10.3892/br.2017.865. View